• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2021.16067

The effectiveness of treatment and features of adverse events in patients with schizophrenia receiving risperidone and haloperidol depending on the duration of illness

[Original research] [Psychiatry]
Elena Kornetova; Anastasia Goncharova; Elena Dmitrieva; Alexander Kornetov; Valeria Gerasimova; Svetlana Ivanova; Arkady Semke;

An assessment was made of the effectiveness of antipsychotic therapy with haloperidol and risperidone in schizophrenic patients who have been hospitalized for 6 weeks, including an assessment of the contribution of antipsychotic adverse events to the dynamics of mental state and the effectiveness of psychopharmacotherapy in the first 10 years of illness. 86 patients with paranoid schizophrenia, 50 (58.1 %) men and 36 (41.9 %) women were examined. The mean age was 30.5±7.4 years. The patients received haloperidol and risperidone as basic therapy. The effectiveness of the therapy received was assessed using the CGI scale. All patients were examined using PANSS and BAS. The presence of metabolic syndrome was established based on the recommendations of the International Diabetes Federation. It was found out that in patients with schizophrenia with disease duration of up to 5 years, risperidone taking was associated with a significant improvement in mental state, and taking of haloperidol – with a slight improvement. It was not possible to establish the contribution of adverse events to the effectiveness of antipsychotic therapy.

Download

References:
1. Rasmussen S. A., Rosebush P. I., Anglin R. E., Mazurek M. F. The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine. Psychiatry Res. 2016;241:72- 77.
https://doi.org/10.1016/j.psychres.2016.04.097
2. Kreyenbuhl J. A., Medoff D. R., McEvoy J. P., Smith T. E., Hackman A. L. [et al.]. The RAISE Connection program: psychopharmacological treatment of people with a first episode of schizophrenia. Psychiatr. Serv. 2016;67(12): 1300-1306.
https://doi.org/10.1176/appi.ps.201500438
3. Keating D., McWilliams S., Schneider I., Hynes C., Cousins G. [et al.]. Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode. BMJ Open. 2017;7(1):e013881.
https://doi.org/10.1136/bmjopen-2016-013881
4. Newton R., Rouleau A., Nylander A. G., Loze J. Y., Resemann H. K. [et al.]. Diverse definitions of the early course of schizophrenia-a targeted literature review. NPJ schizophrenia. 2018;4(1):21.
https://doi.org/10.1038/s41537-018-0063-7
5. Shmukler A. B. Schizophrenia. Moscow: GJeOTAR-Media, 2017:176. (In Russ.).
6. Gómez-Revuelta M., Pelayo-Terán J. M., Juncal-Ruiz M., Vázquez-Bourgon J., Suárez-Pinilla P. [et al.]. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone. Int. J. Neuropsychopharmacol. 2020;23(4):217-229.
https://doi.org/10.1093/ijnp/pyaa004
7. Kahn R. S., Fleischhacker W. W., Boter H., Davidson M., Vergouwe Y. [et al.]. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
https://doi.org/10.1016/S0140-6736(08)60486-9
8. Crespo-Facorro B., Pérez-Iglesias R., Mata I., Martínez-Garcia O., Ortiz V. [et al.]. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology (Berl). 2012;219(1):225-233.
https://doi.org/10.1007/s00213-011-2392-3
9. Correll C. U., Rubio J. M., Kane J. M. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia. World Psychiatry. 2018;17(2):149-160.
https://doi.org/10.1002/wps.20516
10. Lohr J. B., Eidt C. A., Abdulrazzaq Alfaraj A. Soliman M. A. The clinical challenges of akathisia. CNS spectrums. 2015;20(1):1-16.
https://doi.org/10.1017/S1092852915000838
11. Yoshimura B., Sato K., Sakamoto S., Tsukahara M., Yoshimura Y. [et al.]. Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study. Psychopharmacology (Berl). 2019;236(2):723-730.
https://doi.org/10.1007/s00213-018-5101-7
12. Yoca G., Anıl Yağcıoğlu A. E., Eni N., Karahan S., Türkoğ- lu İ. [et al.]. A follow-up study of metabolic syndrome in schizophrenia. Eur. Arch. Psychiatry. Clin. Neurosci. 2020;270(5):611-618.
https://doi.org/10.1007/s00406-019-01016-x
13. World Health Organization ICD-10: Classification of Mental and Behavioural Disorders – Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO, 1992.
14. Schizophrenia with predominance of negative disorders: clinical-constitutional patterns, adaptation, therapy]. Avtoref. dis. … d.m.n. [Abstract of MD thesis]. Tomsk, 2016. (In Russ.).
15. Guy W. NIMH. ECDEU Assessment manual for psychopharmacology, revised. Rockville, MD: US Department of National Institutes of Mental Health, 1976:218-222.
16. Correll C. U., Kishimoto T., Nielsen J., Kane J. M. Quantifying clinical relevance in the treatment of schizophrenia. Clin. Ther. 2012;33(12):B16-39.
https://doi.org/10.1016/j.clinthera.2011.11.016
17. Kay S. R., Opler L. A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13(2):261-276.
https://doi.org/10.1093/schbul/13.2.261
18. Mosolov S. N. Psychometric rating scales of symptoms of schizophrenia and concept of cognitive and negative disorders. M., 2001. (In Russ.).
19. Barnes T. R. A rating scale for drug-induced akathisia. Br. J. Psychiatry. 1989;154(5):672-676.
https://doi.org/10.1192/bjp.154.5.672
20. Gorgun O. V. The relationship between clinical symptoms of schizophrenia and acute drug-induced extrapyramidal disorders. Voennaya medicina. – Military medicine. 2018;45(2):14-20. (In Russ.).
21. The IDF consensus worldwide definition of the metabolic syndrome // International Diabetes Federation, 2006. Available at: https://idf.org/metabolic_syndrome, website of the International Diabetes Federation. Accessed August 7, 2018.
22. Levine S. Z., Rabinowitz J., Engel R., Etschel E., Leucht S. Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI. Schizophr. Res. 2008;98(1-3):318-322.
https://doi.org/10.1016/j.schres.2007.09.006
23. Bardenshtein L. M., Enikeev I., Shcherbakova I. V., Tsygankov B. D., Boev I. V., Aleshkina G. A. Olanzapine in treatment of a schizophrenic patient with orthotopic liver transplant. Medical News of North Caucasus. 2017;12(3):339-341.
https://doi.org/10.14300/mnnc.2017.12094
24. Tsygankov B. D., Boev I. V., Odarchenko S. S. Fundamentals of boundary gerontopsychiatry. Meditsinskii vestnik Severnogo Kavkaza. – Medical News of North Caucasus. 2017;12(2):127-130. (In Russ.).
https://doi.org/10.14300/mnnc/2017.12036
25. Goncharova A. A., Kornetova E. G., Dubrovskaya V. V., Sorokina V. A., Semke A. V Clinical-dynamic and clinicalsocial factors in akathisia in patients with schizophrenia, receiving antipsychotic therapy. Siberian Herald of Psichiatrii and Addiction Psichiatrii. 2018;3(100):46-51. (In Russ.).
https://doi.org/10.26617/1810-3111-2018-3(100)-46-51

Keywords: schizophrenia, haloperidol, risperidone, effectiveness of treatment, akathisia, metabolic syndrome